Financial Reports Latest Updates Industry Maps Economic Calendar

Aclaris Therapeutics, Inc. (ACRS) Annual Reports

Q: Where can I read Aclaris Therapeutics, Inc. (ACRS) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Aclaris Therapeutics, Inc. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1557746 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$1.6M	$1.8M	-8.3%
Operating income	$-24.2M	$-18.4M	-31.7%
Net income	$-21.5M	$-15.4M	-39.4%
EPS (diluted)	$-0.15	$-0.13	-15.4%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 1.63 mn Net income -21.5 mn

Show table：Income statement

Item	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	—	—	—	0	—	—	—	0	—	—	—	—	—	—	—	0.68	1.00	1.12	3.68	1.63	3.67	5.04	5.87	0.98	1.10	1.41	2.05	1.45	1.58	1.78	1.82	1.66	1.50	1.45	1.53	19.0	7.75	2.53	1.87	9.28	17.6	2.40	2.77	4.35	9.21	1.46	1.78	3.30	1.30	2.00	1.63
Gross profit	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.23	0.25	0.15	2.50	0.44	0.16	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating income	-5.26	—	—	-2.66	-2.60	-2.63	-2.60	-10.6	-4.80	-13.1	-13.0	-10.8	-11.6	-12.9	-15.3	-18.8	-25.4	-30.9	-32.0	-33.5	-39.0	-37.3	-49.8	-22.9	-17.6	-15.5	-11.4	-10.5	-13.6	-28.5	-18.0	-20.3	-22.9	-18.9	-21.0	-20.9	-29.1	-29.9	-31.8	-31.6	-4.05	-18.9	-12.8	-10.5	-99.7	-18.1	-18.4	-17.1	-22.7	-22.2	-24.2
Net income	-5.24	-1.03	-2.23	-2.66	-2.60	-2.62	-2.59	-10.6	-4.71	-13.0	-12.9	-10.7	-11.5	-12.6	-14.8	-18.2	-22.9	-30.2	-31.2	-32.7	-38.5	-37.6	-49.9	-55.3	-18.6	-15.6	-11.6	-10.7	-13.2	-28.8	-18.2	-21.1	-22.8	-18.8	-20.5	-19.9	-27.6	-28.2	-29.6	-29.3	-1.49	-16.9	-11.0	-7.59	-96.5	-15.1	-15.4	-14.6	-19.8	-19.8	-21.5

Balance sheet

Quarterly · In mn (USD)

Total assets 180 mn Total liabilities 55.1 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	—	16.3	—	—	39.4	86.5	86.8	95.6	85.6	139	157	176	234	200	192	171	146	180	157	138	145	83.8	82.7	71.0	58.0	57.5	135	241	206	205	191	259	257	232	184	133	123	129	135	118	132	126	109	104	101	96.3	110	97.8
Total assets	—	—	—	—	17.4	—	—	42.1	94.1	87.3	96.1	86.1	176	166	177	261	244	221	202	176	276	253	217	160	98.3	96.8	85.0	71.9	70.8	161	288	263	251	227	278	268	255	230	236	218	197	174	161	182	220	198	189	176	160	199	180
Current liabilities	—	—	—	—	1.45	—	—	1.90	1.56	3.73	5.51	4.59	6.22	5.64	8.37	9.99	12.8	13.8	20.1	22.3	27.3	36.2	42.8	39.0	22.4	20.6	17.8	12.8	14.9	14.5	14.9	17.8	22.9	16.7	16.2	19.8	21.9	18.3	22.8	27.3	30.9	20.1	15.7	18.8	31.6	21.5	26.8	25.6	28.6	27.4	28.2
Total liabilities	—	—	—	—	1.46	—	—	1.90	1.56	4.06	5.85	4.95	6.60	5.92	8.66	17.1	18.3	20.1	27.6	29.9	60.4	70.9	80.0	75.1	28.4	38.6	35.6	31.1	33.1	49.1	54.2	46.9	53.9	46.3	42.2	47.8	57.0	52.9	55.9	62.0	40.2	32.0	27.3	52.2	64.8	54.0	57.4	55.4	57.4	55.1	55.1
Equity	-9.16	—	—	—	-20.8	—	—	-38.1	92.5	83.2	90.2	81.1	169	160	168	244	225	200	174	146	215	182	137	85.3	69.9	58.2	49.4	40.8	37.6	112	234	217	197	180	236	220	198	177	180	156	157	142	134	130	156	144	132	120	103	144	125

Cash flow

Quarterly · In mn (USD)

Operating -19.9 mn Investing 10.3 mn Financing 0.09 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-4.92	—	—	-4.87	-2.76	-2.80	-2.86	-10.6	-4.14	-6.89	-9.73	-9.90	-8.07	-12.7	-10.1	-13.7	-18.2	-21.9	-21.8	-29.9	-27.3	-31.3	-21.4	-23.4	-20.4	-6.80	-10.8	-12.2	-8.86	-12.2	-12.2	-10.6	-17.1	-21.0	-19.7	-7.82	-19.1	-26.4	-20.6	-24.6	-6.76	-20.8	-12.3	22.0	-8.94	-13.1	-9.99	-10.9	-13.1	-18.1	-19.9
Investing	-4.53	—	—	3.59	-5.36	0.75	4.91	-13.1	-69.5	10.2	9.87	-4.13	-77.8	5.96	-0.23	-39.9	-21.6	56.2	13.3	10.4	-70.5	8.62	18.9	21.7	56.4	13.9	-10.5	5.24	-2.31	-75.3	-45.5	-37.7	-9.18	29.9	-21.2	1.22	2.70	25.8	-19.7	32.5	7.55	16.8	-0.67	2.80	-88.7	19.1	5.05	13.8	10.4	-30.9	10.3
Financing	—	—	—	10.6	0	-0.23	-0.66	39.3	58.1	—	18.6	0.01	98.3	0.21	19.3	80.9	-0.08	0.36	-0.3	0.02	128	-0.12	-0.12	-0.07	-30.0	10.9	-0.1	-0.28	7.83	101	136	-11.6	0	0.03	72.8	-0.01	0.04	—	26.7	-0.09	0.05	-0.05	-0.01	0.02	74.6	-0.28	-0.01	-3.04	-2.53	57.8	0.09
Cash at period end	9.59	—	—	18.9	10.8	8.47	9.85	25.4	9.85	13.1	31.8	17.8	30.2	23.7	32.7	60.1	20.2	54.9	46.0	26.6	57.0	34.2	31.6	29.9	34.2	54.0	32.6	23.6	22.1	35.3	113	53.6	27.4	36.3	68.3	61.6	45.3	44.7	31.1	39.0	39.9	35.8	22.8	47.6	24.6	30.4	25.4	25.3	20.0	28.7	19.2

Profitability

Quarterly · %

Gross margin 4.4% Operating margin -1487.9% Net margin -1320.1%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Gross margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	33.8%	24.5%	13.5%	67.9%	26.7%	4.4%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-2742.1%	-2546.8%	-2768.2%	-869.9%	-2054.7%	-1064.0%	-740.6%	-849.0%	-2325.9%	-1603.0%	-1102.1%	-556.3%	-722.2%	-858.2%	-1605.5%	-987.2%	-1223.3%	-1525.2%	-1301.2%	-1374.0%	-109.8%	-375.1%	-1183.5%	-1702.3%	-340.2%	-23.0%	-789.5%	-464.7%	-240.9%	-1082.1%	-1242.9%	-1035.9%	-519.8%	-1755.5%	-1111.8%	-1487.9%
Net margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-2659.7%	-2295.7%	-2703.8%	-849.2%	-2011.1%	-1050.7%	-745.2%	-850.4%	-5627.6%	-1698.1%	-1107.8%	-566.8%	-735.6%	-833.7%	-1618.1%	-995.7%	-1274.6%	-1519.3%	-1293.1%	-1343.7%	-104.9%	-356.4%	-1113.9%	-1582.1%	-315.2%	-8.5%	-706.5%	-397.2%	-174.6%	-1048.2%	-1036.8%	-868.3%	-443.0%	-1528.6%	-993.2%	-1320.1%

Returns & leverage

Quarterly · %

ROE -59.1% ROA -41.1% Debt ratio 30.7%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	—	—	-57.3%	-37.2%	-45.7%	-192.2%	-36.7%	-39.1%	-38.4%	-35.1%	-34.7%	-47.8%	-59.9%	-60.0%	-60.3%	-73.2%	-101.9%	-156.6%	-113.2%	-115.9%	-108.4%	-89.6%	-94.9%	-75.3%	-50.0%	-63.1%	-77.3%	-55.3%	-35.5%	-37.6%	-44.0%	-53.9%	-50.7%	-60.9%	-49.9%	-48.5%	-37.4%	-25.8%	-84.5%	-91.0%	-101.4%	-113.2%	-50.2%	-48.4%	-59.1%
ROA	—	—	—	—	-49.0%	—	—	-43.8%	-36.9%	-35.5%	-42.9%	-64.5%	-35.6%	-37.6%	-36.3%	-32.9%	-32.7%	-44.6%	-54.2%	-53.5%	-51.1%	-59.1%	-75.8%	-107.7%	-86.3%	-79.6%	-66.9%	-48.6%	-60.3%	-49.7%	-37.9%	-48.4%	-56.4%	-41.7%	-29.4%	-30.9%	-34.4%	-42.2%	-41.0%	-47.2%	-39.1%	-38.3%	-29.6%	-18.5%	-63.2%	-70.0%	-76.9%	-79.2%	-34.1%	-35.1%	-41.1%
Debt ratio	—	—	—	—	8.4%	—	—	4.5%	1.6%	4.7%	6.1%	5.8%	3.8%	3.6%	4.9%	6.5%	7.5%	9.1%	13.7%	16.9%	21.9%	28.0%	36.8%	46.8%	28.9%	39.9%	41.9%	43.3%	46.8%	30.4%	18.8%	17.8%	21.4%	20.4%	15.2%	17.9%	22.4%	23.0%	23.7%	28.4%	20.4%	18.4%	16.9%	28.6%	29.4%	27.3%	30.4%	31.6%	35.8%	27.7%	30.7%

EPS

Quarterly · US$

EPS US$-0.15

Show table：EPS

Item	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-3.90	—	—	—	-1.20	-0.57	-0.34	-0.35	-0.37	-0.31	-0.31	-0.30	-0.41	-0.42	-0.42	-0.41	-0.02	-0.24	-0.15	-0.11	-1.21	-0.12	-0.13	-0.12	-0.16	-0.15	-0.15

Revenue & profit

Year-to-date · In mn (USD)

Revenue 3.63 mn Net income -41.3 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 180 mn Total liabilities 55.1 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -38.0 mn Investing -20.7 mn Financing 57.9 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Gross margin 32.1% Operating margin -1280.8% Net margin -1140.1%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -59.1% ROA -41.1% Debt ratio 30.7%

EPS

Year-to-date · US$

EPS US$-0.30

Revenue & profit

Annual · In mn (USD)

Revenue 7.83 mn Net income -64.9 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	—	—	—	—	10.1	13.0	6.48	6.76	29.8	31.3	18.7	7.83
Gross profit	—	—	—	—	3.24	—	—	—	—	—	—	—
Operating income	—	-20.7	-48.6	-72.4	-135	-128	-50.9	-89.7	-89.8	-97.4	-142	-76.4
Net income	-8.52	-20.6	-48.1	-68.5	-133	-161	-51.0	-90.9	-86.9	-88.5	-132	-64.9

Balance sheet

Annual · In mn (USD)

Total assets 160 mn Total liabilities 57.4 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	16.3	86.5	139	200	180	83.8	57.5	205	232	129	126	96.3
Total assets	17.4	94.1	176	244	276	98.3	70.8	251	255	197	220	160
Current liabilities	1.45	1.56	6.22	12.8	27.3	22.4	14.9	22.9	21.9	30.9	31.6	28.6
Total liabilities	1.46	1.56	6.60	18.3	60.4	28.4	33.1	53.9	57.0	40.2	64.8	57.4
Equity	-20.8	92.5	169	225	215	69.9	37.6	197	198	157	156	103

Cash flow

Annual · In mn (USD)

Operating -47.1 mn Investing 48.4 mn Financing -5.86 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	—	-20.4	-34.6	-54.7	-101	-96.4	-38.6	-52.1	-67.6	-78.3	-20.1	-47.1
Investing	—	-77.0	-61.9	-55.7	9.37	106	6.39	-168	12.6	46.2	-69.8	48.4
Financing	—	96.4	—	100	128	-30.3	18.4	225	72.9	—	74.5	-5.86
Cash at period end	10.8	9.85	30.2	20.2	57.0	34.2	22.1	27.4	45.3	39.9	24.6	20.0

Profitability

Annual · %

Gross margin 32.1% Operating margin -975.9% Net margin -829.6%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Gross margin	—	—	—	—	32.1%	—	—	—	—	—	—	—
Operating margin	—	—	—	—	-1341.9%	-982.3%	-785.4%	-1327.1%	-302.0%	-311.6%	-758.1%	-975.9%
Net margin	—	—	—	—	-1315.4%	-1242.7%	-787.0%	-1344.0%	-292.1%	-283.1%	-705.4%	-829.6%

Returns & leverage

Annual · %

ROE -50.2% ROA -34.1% Debt ratio 35.8%

Show table：Returns & leverage

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	-57.3%	-36.7%	-34.7%	-60.3%	-113.2%	-94.9%	-77.3%	-44.0%	-49.9%	-84.5%	-50.2%
ROA	-49.0%	-36.9%	-35.6%	-32.7%	-51.1%	-86.3%	-60.3%	-56.4%	-34.4%	-39.1%	-63.2%	-34.1%
Debt ratio	8.4%	1.6%	3.8%	7.5%	21.9%	28.9%	46.8%	21.4%	22.4%	20.4%	29.4%	35.8%

EPS

Annual · US$

EPS US$-0.53

Show table：EPS

Item	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	—	-1.63	-1.33	-1.27	-1.71	-0.53

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Aclaris Therapeutics, Inc. (ACRS) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.